undamentalytics Newsletter
Sign in

Altimmune, Inc. key statistics and ratios

In fiscal 2025, Altimmune, Inc. had return on equity of -50.6% and a net margin of -214861.0%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Net margin−166.0%−15.6%−342.6%−432.3%−379.2%−353.7%−599.2%<−999%—<−999%<−999%<−999%
Return on equity—−27.1%−46.1%−129.7%−89.3%−43.7%−36.1%−45.7%−44.1%−46.6%−59.9%−50.6%
Return on assets−128.1%−15.2%−36.2%−91.5%−66.5%−37.7%−32.8%−41.9%−39.8%−42.4%−54.3%−42.0%
R&D as % of revenue99.4%87.4%223.1%171.4%178.7%306.2%608.1%>999%—>999%>999%>999%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

4 of 7 checks passed · June 30, 2026
What it owns · $527m
Short-term assets $335mLonger-term assets $192m
What it owes, and who funded it · $527m
Short-term liabilities $13mLonger-term liabilities $41mShareholders' equity $474m
  • Short-term assets cover short-term liabilities $335m of assets due within a year against $13m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $335m short-term assets against $41m of longer-dated liabilities.
  • More cash than debt $63m of cash against $35m of debt.
  • Debt below 40% of shareholders' equity Debt is 7% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 1% to 7% over five years.
  • A year's operating cash flow covers at least 20% of debt −$77m of operating cash flow against $35m of debt.
  • Operating profit covers interest at least five times over Operating income of −$100m against $4m of interest.

From Altimmune, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

9 /100

Weak moat

How hard Altimmune's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -45.2% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -669.5%; its worst year was -515860.0%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 7 years, at a median -189.3% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 703.6% over five years; stock-based pay has been a median 31.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (14 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ALT vs LYELAIM vs ALTALT vs IBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Altimmune, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Altimmune, Inc.